Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727535 | 0.85 | RNASE1 (0.40) | TK1 | |
| SCHEMBL2294 | 0.84 | TK1 (0.43) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL29943756 | 0.84 | TK1 (0.43) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL29364921 | 0.83 | TK1 (0.45) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL16187026 | 0.82 | TK1 (0.44) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL135210 | 0.82 | TK1 (0.44) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL4809531 | 0.82 | TK1 (0.44) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL5580099 | 0.82 | TK1 (0.41) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL5849101 | 0.81 | TK1 (0.43) | TK1LMNAADRA1AALBBLM | |
| SCHEMBL660497 | 0.81 | TK1 (0.45) | TK1LMNAADRA1AALBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963696-B2 | Method for screening mutant microorganism overproducing target metabolite using synthetic suicide genetic circuit | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2018-05-08 | — | — | US | claimed |
| EP-0792369-B1 | SUICIDE GENES AND COMBINATIONS OF PYRIMIDINE NUCLEOSIDE AND NUCLEOBASE ANALOGUES WITH SUICIDE GENES FOR GENE THERAPY | CAYLA (FR) | 2000-04-05 | — | — | EP | claimed |
| US-5856153-A | AN EUKARYOTIC VECTOR CONTAINING TWO EXPRESSION SUCIDE GENE UNITS, FIRST UNIT SENSITIZES TUMOR CELLS TO 5-FLUOROCYTOSINE AND SECOND EXPRESSION SUCIDE GENE UNIT SENSITIZES A MAMMAL CELL OR HIV-INFECTED CELLS TO AZIDOTHYMIDINE NUCLEOSIDE | CAYLA (FR) | 1999-01-05 | — | — | US | claimed |
| EP-0792369-A1 | SUICIDE GENES AND COMBINATIONS OF PYRIMIDINE NUCLEOSIDE AND NUCLEOBASE ANALOGUES WITH SUICIDE GENES FOR GENE THERAPY | CAYLA (FR) | 1997-09-03 | — | — | EP | claimed |
| WO-1996016183-A1 | SUICIDE GENES AND COMBINATIONS OF PYRIMIDINE NUCLEOSIDE AND NUCLEOBASE ANALOGUES WITH SUICIDE GENES FOR GENE THERAPY | CAYLA (FR) | 1996-05-30 | — | — | WO | claimed |
| US-20250188423-A1 | REPROGRAMMING OF SOMATIC CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-06-12 | — | — | US | disclosed |
| EP-3878949-B1 | REPROGRAMMING OF SOMATIC CELLS | WHITEHEAD INST BIOMEDICAL RES (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| EP-3878949-A1 | REPROGRAMMING OF SOMATIC CELLS | Whitehead Institute for Biomedical Research (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20190241874-A1 | REPROGRAMMING OF SOMATIC CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2019-08-08 | — | — | US | disclosed |
| US-10093904-B2 | Reprogramming of somatic cells | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-10-09 | — | — | US | disclosed |
| US-9963696-B2 | Method for screening mutant microorganism overproducing target metabolite using synthetic suicide genetic circuit | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2018-05-08 | — | — | US | disclosed |
| US-5856153-A | AN EUKARYOTIC VECTOR CONTAINING TWO EXPRESSION SUCIDE GENE UNITS, FIRST UNIT SENSITIZES TUMOR CELLS TO 5-FLUOROCYTOSINE AND SECOND EXPRESSION SUCIDE GENE UNIT SENSITIZES A MAMMAL CELL OR HIV-INFECTED CELLS TO AZIDOTHYMIDINE NUCLEOSIDE | CAYLA (FR) | 1999-01-05 | — | — | US | disclosed |
| EP-0792369-A1 | SUICIDE GENES AND COMBINATIONS OF PYRIMIDINE NUCLEOSIDE AND NUCLEOBASE ANALOGUES WITH SUICIDE GENES FOR GENE THERAPY | CAYLA (FR) | 1997-09-03 | — | — | EP | disclosed |
| US-5534519-A | 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-07-09 | — | — | US | disclosed |
| WO-1996016183-A1 | SUICIDE GENES AND COMBINATIONS OF PYRIMIDINE NUCLEOSIDE AND NUCLEOBASE ANALOGUES WITH SUICIDE GENES FOR GENE THERAPY | CAYLA (FR) | 1996-05-30 | — | — | WO | disclosed |
| US-5376658-A | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-12-27 | — | — | US | disclosed |
| WO-1991017660-A1 | 5,10-METHYLENE-TETRAHYDROFOLATE AS A MODULATOR OF A CHEMOTHERAPEUTIC AGENT | SPEARS COLIN P (US) | 1991-11-28 | — | — | WO | disclosed |
| US-4603122-A | 2-DEOXY-D-GLUCOSE | BLOUGH HERBERT A | 1986-07-29 | — | — | US | disclosed |
| US-4315001-A | VINSION DEFECTS; UROGENITAL DISEASES | BLOUGH HERBERT A | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | TK1 17/4885LMNA 1139/4885ADRA1A 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.